Certara, Inc.
CERT scores 32.7 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-1.1 points) applied. CERT's rank of #1023 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| CERT | 32.7 | 95.3 | 8.7% | 2.6% | $1.0B |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| ASND | 78.2 | 16.6 | 98.0% | -31.7% | $13.8B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.4 | 41.9 | 161.5% | -3292.7% | â |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Stock is in a downtrend below the 200-day moving average. Price is below both the 50-day and 200-day SMAs, indicating sustained selling pressure.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $105M | $105M | $106M | $100M |
| Gross Profit | $65M | $64M | $64M | $62M |
| Operating Income | $3M | $10M | $8M | $6M |
| Net Income | $2M | $-2M | $5M | $7M |
| EPS (Diluted) | $0.01 | $-0.01 | $0.03 | $0.04 |
| Gross Margin | 62.0% | 61.1% | 60.8% | 61.9% |
| Operating Margin | 2.9% | 9.1% | 7.2% | 6.0% |
| Net Margin | 1.5% | -1.9% | 4.5% | 6.6% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $23.75 | $45.48 | 62.8% | Wide |
| 2022 | $10.60 | $29.04 | 93% | Wide |
| 2023 | $11.81 | $24.96 | 71.5% | Wide |
| 2024 | $9.41 | $19.87 | 71.4% | Wide |
| 2025 | $8.03 | $15.69 | 64.6% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.